Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Johan A, Dobber"'
Autor:
Iris de Weerdt, Tom Hofland, Renate de Boer, Johan A. Dobber, Julie Dubois, Denise van Nieuwenhuize, Mehrdad Mobasher, Fransien de Boer, Mels Hoogendoorn, Gerjo A. Velders, Marjolein van der Klift, Ester B.M. Remmerswaal, Frederike J. Bemelman, Carsten U. Niemann, Sabina Kersting, Mark-David Levin, Eric Eldering, Sanne H. Tonino, Arnon P. Kater
Publikováno v:
Blood Advances, Vol 3, Iss 17, Pp 2642-2652 (2019)
Abstract: Morbidity and mortality due to immunosuppression remain among the foremost clinical challenges in chronic lymphocytic leukemia (CLL). Although immunosuppression is considered to originate within the lymph node (LN) microenvironment, alterat
Externí odkaz:
https://doaj.org/article/9b70facd4d2e4144a9ac742f72e1a6b0
Autor:
Arnon P. Kater, Marinus H.J. van Oers, Yvette van Norden, Lina van der Straten, Julia Driessen, Ward F.M. Posthuma, Martin Schipperus, Martine E.D. Chamuleau, Marcel Nijland, Jeanette K. Doorduijn, Michel Van Gelder, Mels Hoogendoorn, Francien De Croon, Shulamiet Wittebol, J. Martijn Kerst, Erik W.A. Marijt, Reinier A.P. Raymakers, Martijn R. Schaafsma, Johan A. Dobber, Sabina Kersting, Mark-David Levin
Publikováno v:
Haematologica, Vol 104, Iss 1 (2019)
Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to ev
Externí odkaz:
https://doaj.org/article/fd2f85f1135842ee993a2e9b722ce63a
Autor:
Mark-David Levin, Sabina Kersting, Julie M.N. Dubois, Yvette Norden, Johan A Dobber, Yvonne W.S. Jauw, Anne-Marie van der Kevie-Kersemaekers, Clemens Mellink, Koen de Heer, Leonie van der Burg, Doreen Te Raa, Fransien de Boer, Jolanda Droogendijk, Cecile Idink, Marten R. Nijziel, Lidwine W. Tick, Inge Ludwig, Matthijs Silbermann, Aart Beeker, Mar Bellido, Ludo M. Evers, Gerben JC Zwezerijnen, Carsten U Niemann, Arnon P. Kater
Publikováno v:
Blood. 140:4137-4139
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed1625ac71a83ac6d32654e613af2049
https://doi.org/10.1182/blood-2022-163209
https://doi.org/10.1182/blood-2022-163209
Autor:
Sabina Kersting, Julie Dubois, Kazem Nasserinejad, Johan A Dobber, Clemens Mellink, Anne-Marie F van der Kevie-Kersemaekers, Ludo M Evers, Fransien de Boer, Harry R Koene, John Schreurs, Marjolein van der Klift, Gerjo A Velders, Ellen van der Spek, Hanneke M van der Straaten, Mels Hoogendoorn, Michel van Gelder, Eduardus F M Posthuma, Hein P J Visser, Ilse Houtenbos, Cecile A M Idink, Djamila E Issa, Ellen C Dompeling, Henk C T van Zaanen, Hendrik Veelken, Henriette Levenga, Lidwine W Tick, Wim E Terpstra, Sanne H Tonino, Michelle Boyer, Mehrdad Mobasher, Mark-David Levin, Arnon P Kater
Publikováno v:
The Lancet Haematology, 9(3), e190-e199. Lancet Publishing Group
The Lancet Haematology, 9(3), E190-E199. ELSEVIER SCI LTD
The Lancet Haematology, 9(3), E190-E199. ELSEVIER SCI LTD
Background Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to determine the activity and safety of 12 cycles of venetoclax consolidation after f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0986e715312f80218fa9f8521d8b97ab
https://doi.org/10.1016/s2352-3026(22)00034-5
https://doi.org/10.1016/s2352-3026(22)00034-5
Autor:
Mark-David Levin, Julie Dubois, Rogier Mous, Ellen C Dompeling, Hoa T. T. Tran, Mar Bellido, Christian Bjørn Poulsen, Juha Ranti, Sabina Kersting, Ida Schjødt, Arnon P. Kater, Ann Janssens, Henrik Frederiksen, Clemens Mellink, Johan A. Dobber, Mattias Mattsson, Carsten Utoft Niemann, Lisbeth Enggaard, Gerrit J Veldhuis, Kazem Nasserinejad
Publikováno v:
Blood, 137(8), 1117-1120. AMER SOC HEMATOLOGY
Niemann, C U, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Kater, A P 2021, ' Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia ', Blood, vol. 137, no. 8, pp. 1117-1120 . https://doi.org/10.1182/blood.2020008608
Blood, 137(8), 1117-1120. American Society of Hematology
Niemann, C U, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Kater, A P 2021, ' Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia ', Blood, vol. 137, no. 8, pp. 1117-1120 . https://doi.org/10.1182/blood.2020008608
Niemann, C U, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Kater, A P 2021, ' Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia ', Blood, vol. 137, no. 8, pp. 1117-1120 . https://doi.org/10.1182/blood.2020008608
Blood, 137(8), 1117-1120. American Society of Hematology
Niemann, C U, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Kater, A P 2021, ' Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia ', Blood, vol. 137, no. 8, pp. 1117-1120 . https://doi.org/10.1182/blood.2020008608
ispartof: BLOOD vol:137 issue:8 pages:1117-1120 ispartof: location:United States status: published
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdc9ad8a3176dac8f8c391574fbbaa55
https://hdl.handle.net/11370/98d01a12-fd30-4fee-916b-cdd713c9d5b3
https://hdl.handle.net/11370/98d01a12-fd30-4fee-916b-cdd713c9d5b3
Autor:
Arnon P Kater, Mark-David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, Gerrit J Veldhuis, Rogier Mous, Clemens H M Mellink, Anne-Marie F van der Kevie-Kersemaekers, Johan A Dobber, Christian B Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C Dompeling, Juha Ranti, Christian Brieghel, Mattias Mattsson, Mar Bellido, Hoa T T Tran, Kazem Nasserinejad, Carsten U Niemann
Publikováno v:
The Lancet Oncology, 23(6), 818-828. Lancet Publishing Group
Kater, A P, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, van der Kevie-Kersemaekers, A-M F, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Brieghel, C, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Niemann, C U 2022, ' Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION) : primary analysis of an open-label, randomised, phase 2 trial ', The Lancet Oncology, vol. 23, no. 6, pp. 818-828 . https://doi.org/10.1016/S1470-2045(22)00220-0
Lancet Oncology, 23(6), 818-828. ELSEVIER SCIENCE INC
The Lancet. Oncology, 23(6), 818-828. Lancet Publishing Group
Kater, A P, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, van der Kevie-Kersemaekers, A-M F, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Brieghel, C, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Niemann, C U 2022, ' Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION) : primary analysis of an open-label, randomised, phase 2 trial ', The Lancet Oncology, vol. 23, no. 6, pp. 818-828 . https://doi.org/10.1016/S1470-2045(22)00220-0
Lancet Oncology, 23(6), 818-828. ELSEVIER SCIENCE INC
The Lancet. Oncology, 23(6), 818-828. Lancet Publishing Group
Background Targeted time-limited treatment options are needed for patients with relapsed or refractory chronic lymphocytic leukaemia. The aim of this study was to investigate the efficacy of minimal residual disease (MRD)-guided, time-limited ibrutin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9718c77415d917a2bcc69c56884dfe80
https://research.vumc.nl/en/publications/49812a92-aba6-438b-9c67-b32e46e2a31b
https://research.vumc.nl/en/publications/49812a92-aba6-438b-9c67-b32e46e2a31b
Autor:
Rebecka Svanberg, Rogier Mous, Mattias Mattson, Arnon P. Kater, Sabina Kersting, Hoa T. T. Tran, Kazem Nasserinejad, Carsten Utoft Niemann, Sisse R. Ostrowski, Johan A. Dobber, Mark-David Levin
Publikováno v:
Leukemia & lymphoma, 61(14), 3422-3431. Informa Healthcare
Leukemia and Lymphoma, 61(14), 3422-3431. Informa Healthcare
Leukemia and Lymphoma, 61(14), 3422-3431. Informa Healthcare
Bleeding is a common adverse event following ibrutinib monotherapy. However, it remains unclear how hemostasis is affected by venetoclax in combination with ibrutinib. Here we investigated hemostasis in patients with chronic lymphocytic leukemia (CLL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc0f70b5835d929e019d6156845d5ba8
https://doi.org/10.1080/10428194.2020.1811270
https://doi.org/10.1080/10428194.2020.1811270
Autor:
Karima Amaador, Josephine M. I. Vos, Steven T. Pals, Willem Kraan, Johan A. Dobber, Monique C. Minnema, Harry R. Koene, Peter C. de Bruin, Aiko H. Zwinderman, Marie José Kersten
Publikováno v:
Amaador, K, Vos, J M I, Pals, S T, Kraan, W, Dobber, J A, Minnema, M C, Koene, H R, de Bruin, P C, Zwinderman, A H & Kersten, M J 2022, ' Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression ', Leukemia and Lymphoma, vol. 63, no. 5, pp. 1070-1079 . https://doi.org/10.1080/10428194.2021.2018584
Leukemia and Lymphoma, 63(5), 1070-1079. Informa Healthcare
Leukemia & lymphoma. Informa Healthcare
Leukemia and Lymphoma, 63(5), 1070-1079. Informa Healthcare
Leukemia & lymphoma. Informa Healthcare
Discrimination between Waldenström macroglobulinemia (WM) and marginal zone lymphoma (MZL) of the bone marrow (BM) can be difficult due to overlap in clinical, histopathologic, and immunophenotypic characteristics. We determined which characteristic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09cee69aacff052cb5396507fc932130
https://doi.org/10.1080/10428194.2021.2018584
https://doi.org/10.1080/10428194.2021.2018584
Autor:
Harry R. Koene, Lina van der Straten, J. Martijn Kerst, Sabina Kersting, Arnon P. Kater, Reinier Raymakers, Fatemeh Saberi Hosnijeh, Anton W. Langerak, Mark-David Levin, Mar Bellido, Martijn R. Schaafsma, G. Doreen te Raa, Martine E.D. Chamuleau, Jeanette K. Doorduijn, Marinus H. J. van Oers, Mels Hoogendoorn, Erik W.A. Marijt, Ward Posthuma, Sanne H. Tonino, Fransien de Boer, Michel van Gelder, Johan A. Dobber
Publikováno v:
Experimental Hematology, 89, 55. Elsevier
Experimental hematology, 89, 55-60.e6. Elsevier Inc.
Experimental Hematology, 89, 55-60. ELSEVIER SCIENCE INC
Experimental Hematology, 89, 55-60.e6. Elsevier Inc.
Experimental Hematology, 89, 55-60.e6. ELSEVIER SCIENCE INC
Saberi Hosnijeh, F, van der Straten, L, Kater, A P, van Oers, M H J, Posthuma, W F M, Chamuleau, M E D, Bellido, M, Doorduijn, J K, van Gelder, M, Hoogendoorn, M, de Boer, F, te Raa, G D, Kerst, J M, Marijt, E W A, Raymakers, R A P, Koene, H R, Schaafsma, M R, Dobber, J A, Tonino, S H, Kersting, S S, Langerak, A W & Levin, M-D 2020, ' Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study ', Experimental Hematology, vol. 89, pp. 55-60.e6 . https://doi.org/10.1016/j.exphem.2020.08.002
Experimental hematology, 89, 55-60.e6. Elsevier Inc.
Experimental Hematology, 89, 55-60. ELSEVIER SCIENCE INC
Experimental Hematology, 89, 55-60.e6. Elsevier Inc.
Experimental Hematology, 89, 55-60.e6. ELSEVIER SCIENCE INC
Saberi Hosnijeh, F, van der Straten, L, Kater, A P, van Oers, M H J, Posthuma, W F M, Chamuleau, M E D, Bellido, M, Doorduijn, J K, van Gelder, M, Hoogendoorn, M, de Boer, F, te Raa, G D, Kerst, J M, Marijt, E W A, Raymakers, R A P, Koene, H R, Schaafsma, M R, Dobber, J A, Tonino, S H, Kersting, S S, Langerak, A W & Levin, M-D 2020, ' Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study ', Experimental Hematology, vol. 89, pp. 55-60.e6 . https://doi.org/10.1016/j.exphem.2020.08.002
Despite recent identification of several prognostic markers, there is still a need for new prognostic parameters able to predict clinical outcome in chronic lymphocytic leukemia (CLL) patients. Here, we aimed to validate the prognostic ability of kno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d604aeae92f4f9b8acb5fd120f55dba
https://dspace.library.uu.nl/handle/1874/408766
https://dspace.library.uu.nl/handle/1874/408766
Autor:
Mels Hoogendoorn, Ellen van der Spek, Clemens Mellink, Fransien Croon-de Boer, Julie Dubois, Shulamiet Wittebol, Mehrdad Mobasher, Sanne H. Tonino, Arnon P. Kater, Mark-David Levin, John Schreurs, Cecile Idink, Hein Visser, Yvette van Norden, Sabina Kersting, L. M. Evers, Johan A. Dobber
Publikováno v:
Blood advances, 2(24), 3566-3571. American Society of Hematology
Early data on venetoclax-containing regimens for the treatment of chronic lymphocytic leukemia (CLL) show promising results with deep remissions, but are hampered by potential risk for tumor lysis syndrome (TLS). Whether optimal duration of venetocla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cfc81aa3a7833eaaf846c029226045c
https://doi.org/10.1182/bloodadvances.2018019422
https://doi.org/10.1182/bloodadvances.2018019422